EIF6-224aa directly interacts with the oncogene MYH9 in BC and inhibits the ubiquitin-proteasome pathway and subsequently activates the Wnt/β-catenin pathway to reduce the degradation of MYH9, thereby playing a carcinogenic effect. This evidence concerns the gene MYH9 and breast cancer.